Andrej Dukát, Martin Wawruch, Lucia Mistríková, David Baláž, Martin Čaprnda, Ľudovít Gašpar
Last ESC guidelines in the field of cardiovascular prevention, as well as the results in evidence-based-medicine consistently showed that the LDL-cholesterol lowering is associated with the reduced cardiovascular risk. Optimal LDL cholesterol levels are therefore the primary strategic task in the therapeutical preventive approaches. However, at present increasing attention has focused on the role of inflammation, levels of HDL cholesterol and triglycerides in the process of atherothrombosis. Even the intensified hypolipidemic treatment with statins in the secondary prevention failed to effectively influence still very high residual cardiovascular risk. Therefore the interest of epidemiologists and clinicians is focused on finding the place of combined hypolipidemic treatment in the clinical practice.